ANEB — Anebulo Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $47.25m
- $32.25m
- 34
- 20
- 28
- 16
Annual cashflow statement for Anebulo Pharmaceuticals, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.175 | -30.3 | -6.83 | -11.7 | -8.2 |
| Non-Cash Items | 0.001 | 26.8 | 0.481 | 0.885 | 0.91 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.023 | -1.45 | 0.908 | 1.16 | -0.799 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -0.151 | -4.87 | -5.44 | -9.68 | -8.09 |
| Financing Cash Flow Items | -0.024 | -0.822 | 0 | -0.317 | -0.062 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.18 | 21.8 | 0 | 6.38 | -0.062 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.02 | 17 | -5.44 | -3.3 | -8.15 |